|Articles|June 15, 2002
- BioPharm International-06-01-2002
- Volume 15
- Issue 6
Negotiating and Structuring Strategic Alliances
by David Schulman, Dechert London; and Joe Zammit-Lucia, Chris Easley, Cambridge Pharma Consultancy The job of many a biotech CEO is scrambling to find and secure funds to support the company's development projects. For many biopharmaceutical companies in early development stages, collaboration with "big pharma" is a compelling answer to the cashflow problem. But strategic alliances should benefit those on both sides of the negotiating table.
Advertisement
Articles in this issue
over 23 years ago
Finding Funding in Biotechnology: Keeping the Companies Aliveover 23 years ago
Stem Cells and Xenotransplantation: Ethics, Patents, and Politicsover 23 years ago
Unlocking the Value of R&D: Managing the Risksover 23 years ago
Viewpoint: United Kingdom highlights biomanufacturing capabilitiesover 23 years ago
Inside Washington: Safety, Risk, and Biotechnology Regulationover 23 years ago
Criminal Penalties for Theft of Biological MaterialNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
